The combination of histone deacetylase inhibitors and radiotherapy: a promising novel approach for cancer treatment
- 1 October 2020
- journal article
- review article
- Published by Future Medicine Ltd in Future Oncology
- Vol. 16 (30), 2457-2469
- https://doi.org/10.2217/fon-2020-0385
Abstract
HDAC inhibitors (HDACi) play an essential role in various cellular processes, such as differentiation and transcriptional regulation of key genes and cytostatic factors, cell cycle arrest and apoptosis that facilitates the targeting of epigenome of eukaryotic cells. In the majority of cancers, only a handful of patients receive optimal benefit from chemotherapeutics. Additionally, there is emerging interest in the use of HDACi to modulate the effects of ionizing radiations. The use of HDACi with radiotherapy, with the goal of reaching dissimilar, often distinct pathways or multiple biological targets, with the expectation of synergistic effects, reduced toxicity and diminished intrinsic and acquired resistance, conveys an approach of increasing interest. In this review, the clinical potential of HDACi in combination with radiotherapy is described as an efficient synergy for cancer treatment will be overviewed.Keywords
This publication has 83 references indexed in Scilit:
- Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repairBritish Journal of Cancer, 2013
- Structure of HDAC3 bound to co-repressor and inositol tetraphosphateNature, 2012
- Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinicJournal of Cellular and Molecular Medicine, 2011
- Histone Deacetylase Inhibitors: Emerging Mechanisms of ResistanceMolecular Pharmaceutics, 2011
- Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase InhibitorsJournal of Biomedicine and Biotechnology, 2011
- HDAC Inhibitor, Valproic Acid, Induces p53-Dependent Radiosensitization of Colon Cancer CellsCancer Biotherapy & Radiopharmaceuticals, 2009
- Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenograftsMolecular Cancer Therapeutics, 2009
- Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?British Journal of Cancer, 2008
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006